Hormonal
Treatment with GLP-1 RAs or GIP/GLP-1 RAs significantly reduces the risk of myocardial infarction (MI) and nonfatal MI in overweight or obese adults without diabetes, but does not significantly reduce the risk of stroke.
In non-diabetic overweight or obese adults, GLP-1 and GIP/GLP-1 receptor agonists significantly lower the risk of heart attacks (myocardial infarction), including nonfatal ones. However, these drugs did not show a significant reduction in stroke risk in this specific population, unlike some findings in diabetic patients.
GLP-1 or GIP/GLP-1 RAs reduced the odds of MI (OR: 0.72; 95% CI: 0.61–0.86; p < 0.01; I2 = 0%) and nonfatal-MI (OR: 0.72; 95% CI: 0.61–0.85; p < 0.01; I2 = 0%); while no associations between antiobesity treatment and fatal-MI, stroke, nonfatal, or fatal stroke were uncovered.
Why this rating
Meta-analysis of 16 RCTs with low heterogeneity.
Source
Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis
Maria‐Ioanna Stefanou et al. · Therapeutic Advances in Neurological Disorders · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →